About – Dr. Youram Nassir MD

Founded more than two decades ago by lead oncologist and hematologist Dr Youram Nassir, the Cancer Care Institute specializes in providing innovative, tailored, and thoroughly patient-centered cancer care.

A man in a suit, Dr. Nassir looks directly at lens

Dr. Youram Nassir, MD

Personal Information

Name In FullYouram Nassir, MD
Business Address5901 West Olympic Blvd. Suite 505
Los Angeles, CA 90036
Business Phone(323) 930-2324
Mailing Address311 North Robertson #662
Beverly Hills, CA. 90211
Place of BirthIran
CitizenshipU.S.A.
Email Addressdrnassir@cancer-care-institute.com

Education

College/UniversityUniversity of Toronto, Toronto, Canada
Biology major 1987-1989

University of California, Los Angeles B.S. 
(Double Major: Biology, Iranian Studies) Magna cum Laude 1989-1992
Medical SchoolCornell University Medical College 1992-1994

University of California, Los Angeles School of Medicine 1994-1996
InternshipUniversity of California, Department of Internal Medicine 1996-1997
ResidencyUniversity of California, Department of Internal Medicine 1997-1999
FellowshipUSC Medical Center, Los Angeles, CA
Medical Oncology, Hematology 1999-2002
Board CertificationInternal Medicine, 1999, Board Eligible
Medical Oncology 2002, Board Eligible
Hematology 2002, Board Eligible
Hospital AffiliationsCedars Sinai Medical Center
Olympia Medical Center
Brotman Medical Center- Southern California Hospital

Honors and Awards

1988University of Toronto Faculty Scholar
1991UCLA Medical Center Interpreters and Deaf Services Outstanding Leadership and Service Award
1990-92Melvin Foundation Fellowship for Near Eastern Studies
1991UCLA Chancellors’ Humanitarian Award
1992UCLA Chancellor’s Service Award 1992: Hillel Medical Scholarship
1992Phi Beta Kappa 1989-92: UCLA Dean’s List 1990-92: UCLA   Undergraduate Research Program Certificate of Merit for Outstanding Biomedical Research
1992UCLA Student of the Year for Undergraduate Research 
1992UCLA Outstanding Graduating Senior
1993National Institute of Health Student Scholar
1993American Foundation for Urological Disease, Research Scholarship
2011Yachad Outreach Center Acts of Loving and Kindness Award 

Professional Experience

1989-1992Research Assistant, UCLA Brain Research Institute and Division of Nuclear Medicine, University of California, Los Angeles, California
1993Research Assistant, Department of Urology, Cornell University Medical College
2002-2004Synergy Hematology/Oncology Private Practice
2004Cancer Care Institute   Hematology/Oncology Private Practice

Research Activities

1992Clinical study of adenoid cystic carcinoma. Associate Professor Ophthalmology, UCLA
1989-1992Metabolic and anatomic aspects of brain plasticity including neuroreceptor function and brain energy demands in hemispherectomized rats and cats. Harry Chungani, M.D., Professor, Division of Pediatric Neurology, UCLA. 
1993-1994Characterization and testosterone modulation of imidazoline receptors in rat prostate. Darracott Vaughan, M.D., Professor and Chairman, Department of Urology, Cornell University Medical College
1995Clinical study of the complications of nephrectomy that prevent subsequent immunotherapy in patients with metastatic renal cell carcinoma. Ari Belldegrun, M.0, Professor, Division of Urology, UCLA.
2005A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma (BAM2005). Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2005Studies on the Biology & Treatment of Multiple Myeloma. Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2005A Prospective, Phase I/II Open-Label, Safety & Efficacy Study of Celecoxib Treatment in Patients with Smoldering or Early Stage (I/II) Multiple Myeloma (COXAN 0509-056). Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2005A Stratified, Randomized, Open-label, Multi-center Comparative 2-am Trial of PK, PD and Safety of Zometa Infusions Administered Monthly vs. every 3-month, in Multiple Myeloma Patients with Malignant Bone Lesions, and Breast Cancer Patients with Bone Metastasis, who have Received 9 to 12 Doses of Zometa over the Prior Year (CZOL 446E 2105). Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2005A prospective, Open Label, Safety & Efficacy Study of Combination Treatment with PS-341 & Melphalan in Patients with Relapses or Refractory Multiple Myeloma (134101-009). Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2005A Phase II Study of Belinostat in Combination with Bortezomib in Patients with Relapsed, Refractory Multiple Myeloma. Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2005A Phase I Multi-dose Study of SGN-40 (anti-huCD40 mAb) in Patients with Refractory or Recurrent Multiple Myeloma (SG040-0001). Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2005A Phase II Trial of ZIO 101 in Advanced Multiple Myeloma (SGL2001b).   Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2006A Phase I Study of Samarium Sm-153 Lexidronam Combined with Bortezomib for Patients with Relapsed or Refractory Multiple Myeloma (424Sm35). Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2006A Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety & Efficacy of Single Agent CC-5013 in Subjects Relapsed/Refractory Multiple Myeloma (CC-5013-MM-014). Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2006A Phase I/II Trial of Zio-101 in Advanced Multiple Myeloma (SGL2001). Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2006A Multicenter, Open-label, Randomized Trial Evaluating the Duration of Infusion of Zometa 4 mg IV in Multiple Myeloma Patients with Bone Metastasis. Berenson, James, MD, Sub-investigator: Nassir, Youram, MD, Senior Investigator, ONCO Therapeutics.
2006A Multicenter, randomized, parallel-group, double-blind, placebo-controlled study of combination Thalidomide Plus Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma (THAL-MM-003). Berenson, James, MD, Senior Investigator, and Sub-investigator: Nassir, Youram, MD, and ONCO Therapeutics.
2006A Phase I/II Trial of Zometa in Patients with Monoclonal Gammopathy of Undetermined Significance (ZOMGUS-00S). Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD, ONCO Therapeutics.
2010Randomized, double-blind placebo-controlled phase III study of Regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer who have progressed after standard therapy. Investigator: Nassir, Youram, MD Bayer Healthcare.
2010Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 with Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma.  Investigator: Nassir, Youram, MD Clovis Oncology.
2010Cisplatin and Vinorelbine in combination with Cetuximab as first line treatment for Patients with Advanced Metastatic Non-small Cell Lung Cancer (NSCLC): A Single Arm Multicenter Safety. Investigator: Nassir, Youram, MD Bristol-Myers Squibb.
2013Phase I/II Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients with Relapsed/Refractory Multiple Myeloma, Berenson, James, MD, Senior Investigator, Sub-investigator: Nassir, Youram, MD ONCO
2013Hematology Blood Sample Collection Protocol
2013-2020A Phase 1 Study of Veliparib (ABT-888) in Combination of Gemcitabine and Intensity Modulated Radiation Therapy in Patients with Locally Advanced, Unresectable Pancreatic Cancer.  Investigator: Hendifar, A.E., Wachsman, A.M., Pandol, S.J., Rokhsar, S., Nassir, Youram., Colquhoun, S., Nissen, N., Tuli, R., Sandler, H.M
OngoingA Phase 2 Study of Weekly 70mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Publications (Peer Review)

  1. Rocha L, Ackerman RF, Nassir Y, Chugani HT, Engel J. “Characterization of My Opioid Receptor Binding During Amygdala Kindling in Rats and Effects of Chronic Naloxone Pre-Treatment: and Autoradiographic Study.” Epilepsy Research 14:195-208, 1993.
  2. Nassir Y, Regunathan S, Reis DJ, Vaughan ED Jr, Felsen D. “Castration of Rats Upregulates the Imidazoline Receptor in Prostate.” Ann NY Acad Sci 763:174177. 1995.
  3. Rugunathan S, Nassir Y, Sundaram K, Vaughan ED Jr, Reis DJ, Felsen D. “Expression of I Imidazoline Receptor in Rat Prostate and Regulation by Testosterone.” J BioChem Pharmacol (Submitted), 1999
  4. Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee S-P, Wilson J, Yellin O, Morrison B, Hilger J, and Swift RA, “Safety and Efficacy of Bortezomib and Melphalan Combination in Patients with Relapsed or Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study After Longer Follow-up,” Annals of Hematology, 87:623-631 (2008)
  5. Berenson JR, Yellon O, Boccia RV, Flam M, Wong S-F, Batuman O, Moezi MM, Woytowitz, D, Duvivier H, Nassir Y, and Swift RA, “Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss,” Clinical Cancer Res, 14(19):6289-6295 (October 1, 2008)
  6. Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R, Abaya CD, and Swift RA, “A Phase 1 Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma,” Clinical Cancer Res, 15(3):1069-1075 (2009)
  7. Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, Eades B, Abaya CD, Hilger J, and Swift RA, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients with Newly Diagnosed Multiple Myeloma: and Effective and Well-tolerated Frontline Regimen,” Eur J Haematol, 82:432-439 (2009)
  8. James R Berenson, Ori Yellin, Alan Carmell, Thomas Woliver, Marshall Flam, Youram Nassir, Robert Vescio, and Regina a Swift, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed /Refractory (R/R) Multiple Myeloma (MM),” American Society of Hematology Annual Meeting, 116:4936 (November 2010) 
  9. Berenson JR, Yellin O, Crowley J, Makary A, Gravenor D, Yang H, Upadhyaya G, Flinn I, Staszewski H, Tiffany N, Sanani S, Farber C, Morganstein N, Bolejack V, Nassir Y, Sefardi A, Shamouelian A, and Swift R, “Prognostic Factors and Jaw and Renal Complications Among Multiple Myeloma Patients Treated with Zoledronic Acid” Am J Hematology, 110:25-30 (2011).
  10. Berenson JR, Yellin O, Kazamel T, Hilger JD, Chen CS, Cartmell A, Woliver T, Flam M, Bravin E, Nassir Y, Vescio R, and Swift RA, “A Phase 2 Study of Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Patients with Relapsed/Refractory Multiple Myeloma,” Leukemia, 26(7):1675-80 (2012).
  11. Berenson JR, Hilger JD, Yellin O, Boccia R, Matous J, Dressler K, Ghazal H, Jamshed S, Kingsley EC, Harb WA, Noga SJ, Nassir Y, Swift RA, and Vescio R, “A Phase 1/2 Study of Oral Panobinostat Combined with Melphalan for Patients with Relapsed or Refractory Multiple Myeloma,” Ann Hematol, 93:89-98 (2014).
  12. Berenson JR, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, Bessudo A, Stampleman, Gravenor D, Eshaghian S, Nassir Y, Swift RA, and Vescio RA, “Replacement of Bortezomib with Carfilzomib for Multiple Myeloma Patients Progressing from Bortezomib Combination Therapy,” Leukemia, 28(7):1529-1536 (2014).
  13. Berenson JR, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, Sanani S, Shlutz M, Nassir Y, Swift RA, Andreu-Vieyra C, and Vescio R, “A Phase 3 Trial of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients with Multiple Myeloma,” Supportive Care Cancer (2015) 23:1503–1512

Abstracts (Published)

  1. Kunchandy J, Chugani MT, Nassir Y. “Hemidecortication in Rat Pups: Effects on Local Cerebral Metabolic Rates for Glucose in Adulthood”. Ann Neurol 28A12, 1990.
  2. Tatsukawa K, Chugani NT, Brown O, Nassir Y. “Chronic Cerebral Glucose Metabolic Rates in Hemidecorticated Rats are Dependent on Age-at-Lesion J Cerebral Blood Flow and Metabolism” 11 (2):S794, 1991.
  3. Rocha L, Engel J Jr, Nassir Y, Chugani HT. “Effects of Upregulation of Opioid Receptors on Amygdaloid Kindling in Rats and its Association with Mu Opioid Receptor Levels.” Epilepia 32(1):33, 1991.
  4. Nassir Y, Tatsukawa K, Villablanca J, Chugani NT. Increased 3H-Flunitrazepam Binding in Visual Structures of Adult Cerebral Hemispherectomized Compared to Neonatal Hemispherectomized Cats. Soc Neurosci Abstracts 17:894, 1991.
  5. Yellin O, Crowley J, Swift R, Duvivier H, Nassir Y and Berenson J, “Factors that Determine Overall Survival Among Patients with Multiple Myeloma Treated with Zoledronic Acid,” Clin Exp Metastasis, Proceedings of Skeletal Complications of Malignancy V, Philadelphia, PA 25 Suppl:2008: Abstract # S32:29 (October 25-27, 2007)
  6. Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Y, and Swift RA, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen,” 2007 American Society of Hematology (ASH) Meeting Abstracts, Blood, Part I, Vol110, Issue 11, Abstract # 3602 (11/2007)
  7. Berenson JR, Yellin O, Boccia RV, Flam MS, Wong S-F, Batuman O, Moezi MM, Woytowitz D, Duvivier H, Nassir Y, and Swift RA, “Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (PTS.) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss,” 2007 American Society of Hematology (ASH) Meeting Abstracts, Blood, Part I, Vol. 110, Issue 11, Abstract# 3606 (11/ 2007).
  8. Berenson JR, Yellon O, Crowley J, Duvivier H, Nassir Y, and Swift RA, “Factors that Determine Overall Survival among Patients (Pts) with Multiple Myeloma (MM( Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival,” 2007 American Society of Hematology (ASH) Meeting Abstracts, Blood, Part I, Vol. 110, Issue 11, Abstract # 4842 (11/2007)
  9. Berenson JR, Yellon O, Crowley J, Duvivier H, Nassir Youram, and Swift RA, “Factors that Determine Overall Survival Among Patients (Pts) with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival,” American Society of Hematology 49th Annual Meeting, Abstract # 955145, 2007
  10. Berenson JR, Yellin O, Boccia RV, Flam MS, Wong S-F, Bautman O, Moexi MM, Woytowitz D, Duvivier H, Nassir Youram, and Swift RA, “Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.” American Society of Hematology 49th Annual Meeting, Abstract $# 956660, 2007
  11. Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R, Duvivier H, Nassir Youram, and Swift RA, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-tolerated Frontline Regimen.” American Society of Hematology 49th Annual Meeting, Abstract # 956738, 2007
  12. Berenson JR, Yang HH, Vescio RA, Nassir Youram, Mapes R, Lee S-P, Wilson J, Yellin O, Morrison B, Hilger J, and Swift RA, “Safety and Efficacy of Bortezomib and Melphalan Combination in Patients with Relapsed or Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study After Longer Follow-up,” Annals of Hematology, 87:623-631 (2008)
  13. Berenson JR, Yellin O, Boccia RV, Flam MS, Wong S, Batuman O, Moezi MM, Woytowitz DV, Duvivier HL, Nassir Youram, and Swift R, “Marked improvement in bone mineral density (BMD) for patients (pts.) with monoclonal Gammopathy of undetermined significance (MGUS) using Zoledronic acid (ZOL), J Clin Onol 26: 2008 (May 20 supplement; abstract 8550)
  14. Berenson JR, Yellin O, Crowley J, Makary A, Gravenor DS, Yang HH, Upadhyaya GH, Flinn IW, Staszewski H, Tiffany NM, Sanani S, Farber CM, Morganstein N, Duvivier H, Nassir Youram, Sefardi A, Shamouelian A, and Swift RA. “Overall Survival Among Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL).” XII International Myeloma Workshop, Washington, DC, Clin Lymph & Myeloma, 9: Abstract 088 (February 2009)
  15. Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Youram, Mapes R, Abaya CD, and Swift RA, “A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma,” Clin Cancer Res, 15(3):1069-1075 (2009)
  16. Berenson JR, Yellin O, Boccia RV, Nassir Youram, Rothstein S, and Swift R, “A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM),” 2009 American Society of Hematology Annual Meeting Abstracts    114(22): Abstract # 1855:736 (December 2009)
  17. Berenson JR, Donahue DB, Yellin O, Upadhyaya G, Nassir Youram, Swift RA, “A Randomized Trial Evaluating a New Powered Bone Marrow Aspirate and Core Biopsy System Compared to Traditional Manual Devices,” 2009 American Society of Hematology Annual Meeting Abstracts, 114(22): Abstract # 4234 (December 2009)
  18. Berenson JR, Yellin O, Patel R, Chen C-S, Boccia RV, Colbourn D, Yang H, Gupta V, Geils GF, Nassir Youram, Hilger J, and Swift R, “A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM), “2009 American Society of Hematology Annual Meeting Abstracts, 114(22): Abstract # 4936 (December 2009). 
  19. Berenson JR, Yellin O, Cartmell A, Woliver T, Flam M, Nassir Youram, Vescio R, and Swift RA, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), “Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” American Society of Hematology Annual Meeting, Blood 116:4936 (November 2010).
  20. Ori Yellin1, James R. Berenson1, 2, 3, Ralph V. Boccia4, Allen Cohn5, Paul Berard6, Hassan Ghazal7, Saad Jamshed8, Edwin Kingsley9, Wael Harb10, Stephen J. Noga11, Youram Nassir 12, Regina A. Swift2 and Robert Vescio13 Phase 1/2 trial of melphalan (MEL) combined with Panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM).
  21. Berenson J, Yellin O, Kazamel T, Boccia R, Matous J, Dressler K, Nassir Youram, Rothstein S, and Swift, R, “A Phase I/II Study of Oral Melphalan (MEL) Combined with Panobinostat (PAN) for Patients with Relapsed or Refractory (R/R) Multiple Myeloma (MM),” International Myeloma Workshop (submitted for the 2011 meeting).
  22. Berenson J, Yellin O, Kazamel T, Cartmell A, Woliver T, Flam M, Nassir Youram, Vescio R, and Swift R, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” International Myeloma Workshop (submitted for the 2011 meeting).
  23. Yellin O, Berenson JR, Kazamel T, Chen C-S, Cartmell A, Woliver T, Flam M, Bravin E, Nassir, Youram, Vescio R, and Swift RA, “A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncology, presented at ASCO meeting, 29:524s, abstract #8082 (June, 2011).
  24. Kazamel T, Berenson JR, Yellin O, Boccia RV, Matous J, Dressler KA, Nassir Youram, Rothstein S, and Swift R, “A Phase I/II Study of Oral Melphalan (MEL) Combined with Panobinostat (PAN) for Patients with Relapsed or Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncology, 29: abstract e18574 (June 2011).
  25. Berenson J, Yellin O, Boccia R, Matous J, Dressler K, Jamshed, Kingsley, Harb, Noga, Nassir Youram, and Swift R, “A Phase 1/2 Trial of Melphalan (MEL) Combined with Panobinostat (PAN) for Patients with Relapsed or Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncology, submitted for ASCO meeting 2012.
  26. Berenson J, Yellin O, Dichmann R, Patel-Donnelly D, Boccia R, Hilger J, Nassir Youram, Swift R, and Vescio R, “A Phase I/II Study of Carfilzomib as a Replacement for Bortezomib for Multiple Myeloma Patients Progressing While Receiving a Bortezomib-Containing Combination Regimen,” J Clin Oncology, abstract #8098 submitted for ASCO meeting 2012.
  27. Berenson JR, Hilger J, Klein L, Eshaghian S, Nassir Youram, Swift R, and Vescio R, “A Phase ½ Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin in Patients with Relapsed/Refractory Multiple Myeloma,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 120 Abstract 2979 (November 2012).
  28. Berenson JR, Hilger J, Dischmann R, Patel-Donnelly D, Boccia R, Bessudo A, Stampleman L, Gravenor D, Eshaghian S, Nassir Youram, Swift R, and Vescio R, “A Phase I/II Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts.) Refractory to a Bortezomib-Containing Combination Regimen,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 120 Abstract 4063 (November 2012).
  29. Berenson JR, Hilger J, Dichman R, Patel-Donnelly D, Boccia R, Bessudo A, Stampleman L, Gravenor D, Eshaghian S, Chamras H, Nassir Youram, Swift R, and Vescio R, “Multiple Myeloma (MM) Patients (PTS.) Progressing While Receiving a Bortezomib (BTZ)-Containing Combination Regimen Frequently Respond When Carfilzomib (CFZ) Replaces BTZ: A Phase I/II Study,” J Clin Oncol 31, 2013 (suppl; abstr 8599)
  30. Hilger J, Berenson JR, Klein L, Bessudo A, Rosen P, Eshaghian S, Chamras H, Nassir Youram, Swift R, and Vescio R, “A Phase I/II Study of Pomalidomide (POM), Dexamethasone (DEX) and Pegylated Liposomal Doxorubicin (PLD) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM),” J Clin Oncol 31, 2013 (suppl; abstr 8598)
  31. Berenson JR, Yellin O, Kazamel T, Hilger JD, Chen CS, Cartmell A, Woliver T, Flam M, Bravin E, Nassir Youram, Vescio R, and Swift RA, “A Phase 2 study of pegylated liposomal doxorubicin, Bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma,” Leukemia, 26(7): 1675-80 (2012).
  32. Berenson JR, Klein L, Rosen P, Woliver T, Eshaghian S, Nassir Youram, Swift RA, and Vescio R, “Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1/2 Trial,” American Society of Hematology (ASH Annual Meeting Abstracts) Blood 122(21):3218 (November 2013).
  33. Berenson JR, Klein L, Rosen P, Woliver T, Eshaghian S, Nassir Youram, Swift RA, and Vescio R, “A Phase I/II Study of Pomalidomide (POM), Dexamethasone (DEX) and Pegylated Liposomal Doxorubicin (PLD) for Patients with Relapsed/Refractory Multiple Myeloma (RRMM),” J Clin Oncol 32, 2014 (suppl; abstr e19586^).
  34. Berenson JR, Klein L, Rosen P, Woliver T, Eshaghian S, Nassir Youram, Swift RA, and Vescio R, “A Phase I/II Study of Pomalidomide (POM), Dexamethasone (DEX) and Pegylated Liposomal Doxorubicin (PLD) for Patients with Relapsed/Refractory Multiple Myeloma (RRMM),” J Clin Oncol 32, 2014 (suppl; abstr e19586^).
  35. Lepor, Norman E., Nassir Youram, “Evaluation of Long-term Cardiovascular Effects”, Reviews in Cardiovascular Medicine, 15 (1) 2014.
  36. Berenson JR, Stampleman, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam MS, Eshaghian S, Nassir Youram, Swift RA, and Vescio R, “A Phase 1 /2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma,” Blood 124(21):3469 (December 2014).
  37. Berenson J, Stampleman L, Bessudo A, Rose PJ, Klein L, Woliver T, Flam M, Eshaghian S, Nassir Youram, Swift RA, Wang J, Benjamin E, Spektor TM, and Vescio R, “a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM),” submitted for the American Society of Hematology Annual Meeting (2015).
  38. Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Youram, Eades B, Swift R, and Berenson JR, “Improved Clinical Outcomes for Multiple Myeloma Patients Treated at a Single Specialty Clinic,” Annals of Hematol. 96:441-448 (2017).
  39. Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Youram, Eades B, Swift R, and Berenson JR, “Outcomes of Multiple Myeloma Patients Receiving Bortezomib, Lenalidomide and Carfilzomib,” Annals of Hematol. 96:449-459 (2017).
  40. Vidisheva AP, Wang J, Spektor TM, Bitran JD, Lutzky J, Tabbara IA, Ye JZ, Ailawadhi S, Stampleman LV, Steis RG, Moezi MM, Swift RA, Maluso TM, Udd KA, Eshaghian S, Nassir Youram, and Berenson JR, “Manifestation of Peripheral Neuropathy in Multiple Myeloma Patients with Bortezomib Retreatment,” J Supportive Care Cancer. e-published on April 28, 2017.
  41. Cohen A, Spektor TM, Stampleman, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam M, Eshaghian S, Nassir Youram, Swift RA, Vescio R, and Berenson JR, “Safety and Efficacy of Pomalidomide (POM), Dexamethasone (DEX) and Pegylated Liposomal Doxorubicin (PLD) for Patients with Relapsed and Refractory Multiple Myeloma (RRMM), epublished Nov 21, 2017,Br J Haematol. 2018 Jangallb
  42. Berenson JR, To J, Spektor TM, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift A, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss R, Nassir Youram, Patel R, Bessudo A, Lim S, Vescio R. “A Phase 1 Trial of Ruxolitinib, Lenalidomide, and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” American Society of Clinical Oncology Annual Meeting. June 2019. Chicago, IL. 
  43. Berenson JR, To J, Spektor T, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift R, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss R, Nassir Youram, Patel R, Bessudo A, Lim S, Vescio R. “A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” 17th International Myeloma Workshop. September 2019 (submitted)
  44. Berenson JR, To J, Spektor TM, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift A, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss R, Nassir Youram, Patel R, Bessudo A, Lim S, and Vescio R. “A Phase 1 Trial of Ruxolitinib, Lenalidomide, and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” J Clin Oncol 37, 2019 (suppl: abstr 8048). 
  45. Berenson JR, To J, Spektor TM, Martinez D, Sanchez A, Ghermezi M, Turner C, Swift R, Eades B, Schwartz G, Eshaghian S, Stampleman L, Moss RA, Nassir Youram, Patel R, Bessudo A, Greenwald D, Boccia R, Lim S, and Vescio R. “A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM),” Blood . 134 (Supplement 1):1903 (2019).
  46. Chen H, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir Youram, Huang J, Daniely D, Wang C, Xu N, and Berenson JR. “The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma,” Blood. 134 (Supplement 1):4352 (2019).
  47. Xu N, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir Youram, Yu J, Huang J, Daniely D, Wang C, Chen H, and Berenson JR. “The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma,” Blood. 134 (Supplement 1):1824 (2019).
  48. Chen H, Li M, Sanchez E, Ng N, Yu E, Bujarski S, Yin Z, Hekmati T, Field D, Wang J, Nassir Youram, Yu J, Huang J, Daniely D, Wang C, Xu N, and Berenson JR. “Ruxolitinib Reverses Checkpoint Inhibition by Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma,” Blood. 134 (Supplement 1):4402 (2019).
  49. Chorath J, Placenico-Hickok V, Guan M, Nissen N, Kamrava M, Klempner S, Nassir Youram, Hendifar A, Gong J. “Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic Hight-Grade Neuroendocrine Carcinoma of the Gallbladder, Pancreas 2020 02-49(2) e19-e20 February 2020

Presentations

1991Brown D, Chen S, Tatsukawa K, Nassir, Youram, Nevda D, Viflablanca J, Chugani HT. Muscarinic Cholinergic Receptor Binding Following Neonatal and Adult Hemispherectomy in the Cat. American Epilepsy Society, 1991.
1994Nassir, Youram, Regunattran S, Reis DJ, Vaughan ED Jr Felsen D. Castration of Rats Upregulates the Imidazoline Receptor in Prostate. International Conference on Imidazoline Receptor, 1994.
2013Guest Speaker at the Sickle Cell Family Education Day: Moving Towards Independence; May 18, 2013 for the Children’s Hospital Los Angeles.  Nassir, Youram, MD.
2014Guest Speaker at the 3nrd Annual West Coast Sickle Cell Nurses Conference; August 4, 2014; Topic “Living With Sickle Cell Disease”. Nassir, Youram, MD.
2016Guest Speak at the Annual Sickle Cell Disease Picnic: August 7, 2016: Nassir, Youram, MD.

Please fill out the form below to contact Dr. Nassir and the Cancer Care Institute.

  • This field is for validation purposes and should be left unchanged.